Table 1 Summary of engineered probiotics for diagnosis and therapy
From: Engineered probiotics
Disease | Probiotic used | Object | Refs. |
|---|---|---|---|
Clostridioides difficile infection | An S. boulardii strain | Mice | [5] |
Cancer | E. coli Nissle 1917 | Mice | [6] |
Cancer | E. coli Nissle 1917 | Mice | [7] |
Cancer | E. coli Nissle 1917 | Mice | [8] |
Cancer | E. coli Nissle 1917 | Mice | [9] |
Cancer | E. coli Nissle 1917 | Mice and human | [10] |
Cholera | L. lactis CSL | Mice | [11] |
Colitis | E. coli Nissle 1917 | Mice | [12] |
Diabetes | L. gasseri ATCC 33,323 | Rats | [13] |
Hyperammonemia | E. coli Nissle 1917 | Mice and human | [14] |
Inflammatory bowel disease | E. coli Nissle 1917 | Mice | [15] |
Inflammatory bowel disease | E. coli NGF-1 | Mice | [16] |
Inflammatory bowel disease | E. coli Nissle 1917 | In vitro | [17] |
Inflammatory bowel disease | E. coli Nissle 1917 | Mice | [18] |
Inflammatory bowel disease | E. coli Nissle 1917 | Mice | [19] |
Inflammatory bowel disease | Yeast strain BS016 | Mice | [20] |
Inflammatory bowel disease | E. coli Nissle 1917 | Mice | [21] |
Listeria infection | L. casei ATCC334 | Mice | [22] |
Obesity | E. coli Nissle 1917 | Mice | [23] |
Phenylketonuria | L. reuteri 100-23C | Mice | [24] |
Phenylketonuria | E. coli Nissle 1917 | Human | [25] |
Pseudomonas aeruginosa Infection | E. coli Nissle 1917 | Caenorhabditis elegans and mice | [26] |
Staphylococcus aureus Infection | L. reuteri DSM20016 | In vitro | [27] |
Ulcerative colitis | E. coli Nissle 1917 | Mice | [28] |
Vancomycin-resistant Enterococci infection | E. coli Nissle 1917 | Mice | [29] |